Biogen Deepens Immunology Presence With Apellis Acquisition

Biogen has significantly expanded its immunology and rare disease portfolio through the acquisition of Apellis Pharmaceuticals, a move that includes a total transaction value of approximately $5.6 billion. The agreement marks a major strategic shift for Biogen as it integrates Apellis’ advanced complement-immunotherapy platform and its specialized workforce of 733 employees, further deepening its footprint in the Massachusetts biotechnology corridor.

The acquisition adds two fast-growing commercial-stage therapies to Biogen’s portfolio: SYFOVRE®, the first FDA-approved treatment for geographic atrophy (GA), and EMPAVELI®, approved for paroxysmal nocturnal hemoglobinuria (PNH) and rare kidney disorders. With these additions, Biogen broadens its revenue base beyond its traditional neurology business while strengthening its position in the expanding nephrology market.

The deal also highlights the growing strategic role of regional biotech hubs in fostering large-scale innovation. Massachusetts has maintained its status as a premier life sciences center for decades, but the scale of the current integration signals a broader shift toward consolidated regional infrastructure. Beyond product pipelines, such acquisitions are expected to contribute to job preservation, infrastructure modernization, and long-term economic stability within the Cambridge and Waltham research ecosystems.

According to Christopher A. Viehbacher, President and Chief Executive Officer of Biogen, “This strategic acquisition of Apellis marks a significant step in strengthening our immunology portfolio and advancing our commitment to patients with rare diseases. Together, we are leveraging specialized scientific expertise to deliver breakthrough therapies that support long-term growth and accelerate the transition to a more diversified therapeutic future.”. He emphasized that integrating the Apellis workforce highlights the increasing value of human capital in the evolving life sciences landscape. The acquisition is expected to strengthen Biogen’s global commercial reach while advancing its long-term R&D objectives through the retention of specialized talent experienced in managing complex clinical development lifecycles.